Table 1.

List of Studied Cancer Drugs

Trade Name	FDA Approval Year	Target Disease	Pivotal Clinical Trial
			Trial Sites	Patients Enrolled	Publication Year	Number of Trial Authors	First Author City
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Xeloda	1998	Breast cancer	25	163	1999	10	Dallas
Herceptin	1998	Breast cancer	54	222	1999	11	Chicago
Valstar	1998	Bladder cancer	41	90	2000	6	Chicago
Ontak	1999	Cutaneous T-cell lymphoma	25	71	2001	26	Durham
Temodar	1999	Brain cancer	21	225	2000	22	Houston
Ellence	1999	Breast cancer	39	710	1998	18	Canada
Mylotarg	2000	Acute myeloid leukemia	32	104	2001	17	Seattle, WA
Trisenox	2000	Acute myeloid leukemia	9	40	2001	15	New York
Campath	2001	Chronic lymphocytic leukemia	21	93	2002	11	Houston
Zometa	2001	Hypercalcemia of malignancy	87	287	2001	11	Canada
Zevalina	2002	Non-Hodgkin’s lymphoma	45	200	2002	13	Rochester, MN
Faslodex	2002	Breast cancer	83	400	2002	14	Houston
Eloxatin	2002	Colon cancer	120	463	2003	8	Nashville, TN
Velcadeb	2003	Multiple myeloma	14	202	2003	21	Boston
Bexxar	2003	Non-Hodgkin’s lymphoma	3	40	2005	7	Stanford, CA
Alimta	2004	Lung cancer	88	456	2003	13	Chicago
Erbitux	2004	Colon cancer	56	329	2004	12	United Kindom
Avastin	2004	Colon cancer	164	923	2004	15	Durham, NC
Dacogen	2006	Myelodysplastic syndromes	23	170	2006	16	Houston
Arranon	2006	Colon cancer	81	463	2007	12	Belgium
Torisel	2007	Kidney cancer	148	626	2007	19	Philadelphia

^aThere were two pivotal trials for Zevalin; the second trial had 11 authors, with the same first author also in Rochester, Minnesota.

^bThere were two pivotal trials for Velcade; the second trial had fifteen authors, with the first author in New York.